National Research Co. (NASDAQ:NRC) Director Donald M. Berwick sold 6,989 shares of National Research stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $62.04, for a total transaction of $433,597.56.
Shares of NRC stock traded up $0.35 on Friday, reaching $58.18. 31,809 shares of the stock were exchanged, compared to its average volume of 79,313. The company has a current ratio of 0.62, a quick ratio of 0.62 and a debt-to-equity ratio of 1.24. The business’s 50 day moving average price is $61.39 and its 200 day moving average price is $41.10. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of 55.94 and a beta of 0.77. National Research Co. has a twelve month low of $35.65 and a twelve month high of $68.86.
National Research (NASDAQ:NRC) last issued its earnings results on Tuesday, August 6th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.03. National Research had a net margin of 24.59% and a return on equity of 124.11%. The company had revenue of $31.41 million for the quarter, compared to analyst estimates of $30.26 million.
Separately, ValuEngine downgraded shares of National Research from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd.
Hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its position in National Research by 0.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 733,832 shares of the company’s stock worth $27,989,000 after acquiring an additional 3,622 shares during the last quarter. BlackRock Inc. boosted its position in National Research by 7.5% during the second quarter. BlackRock Inc. now owns 709,948 shares of the company’s stock worth $40,885,000 after acquiring an additional 49,361 shares during the last quarter. Conestoga Capital Advisors LLC boosted its position in National Research by 2.6% during the second quarter. Conestoga Capital Advisors LLC now owns 626,878 shares of the company’s stock worth $36,102,000 after acquiring an additional 15,789 shares during the last quarter. Vanguard Group Inc. raised its stake in National Research by 10.3% during the second quarter. Vanguard Group Inc. now owns 562,951 shares of the company’s stock worth $32,421,000 after purchasing an additional 52,656 shares during the period. Finally, Renaissance Technologies LLC raised its stake in National Research by 4.3% during the second quarter. Renaissance Technologies LLC now owns 513,800 shares of the company’s stock worth $29,590,000 after purchasing an additional 21,100 shares during the period. Institutional investors and hedge funds own 36.03% of the company’s stock.
National Research Company Profile
National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company’s portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement.
Recommended Story: What are gap-down stocks?
Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.